Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMD8ZSW)

Drug Name

Rilotumumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Grade IV malignant glioma	2A00.0	Discontinued in Phase 2	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatocyte growth factor (HGF)	TT4V2JM	HGF_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Hepatocyte growth factor (HGF)	DTT	HGF	5.784	3.307	4.868	1.926

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Grade IV malignant glioma

ICD Disease Classification

2A00.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Hepatocyte growth factor (HGF)	DTT	HGF	4.90E-01	0.13	2.73
Hepatocyte growth factor (HGF)	DTT	HGF	1.98E-07	1.58	2.92

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7986).
2	Clinical pipeline report, company report or official report of Amgen (2009).